⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RNAZ News
TransCode Therapeutics, Inc. Common Stock
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors
prnewswire.com
RNAZ
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
prnewswire.com
RNAZ
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO
prnewswire.com
RNAZ
TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company
prnewswire.com
RNAZ